uPAR: a beacon of malignancy? SUMMARY Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient care. 